CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) projected adjusted earnings growth of 8% to 10% for fiscal 2027 after reporting $337.4 billion in annual revenue, as the pharmaceutical distributor expands its specialty healthcare operations and reorganizes its business around higher-growth markets.
The company expects adjusted diluted earnings per share of $19.40 to $19.75 in fiscal 2027, compared with $17.97 in fiscal 2026, according to its latest earnings report.
Fourth-quarter revenue increased 5.5% to $88.4 billion for the period ended Sept. 30, 2026, while adjusted diluted earnings per share rose 21.4% to $4.66 from $3.84 a year earlier.
Reported earnings improved to $2.71 per diluted share, reversing a loss of $1.75 per share in the prior-year quarter. The comparison reflects, in part, a $723.9 million goodwill impairment charge associated with PharmaLex in the previous year.
The results follow Cencora’s February acquisition of OneOncology, which expanded its position in specialty healthcare services and contributed to higher profitability in its U.S. operations.
Fourth-quarter gross profit increased 21.9% to $3.6 billion, substantially outpacing revenue growth. Gross margin rose 55 basis points to 4.08%, primarily reflecting the contribution from OneOncology.
That improvement was partially offset by increased sales of GLP-1 medications used to treat diabetes and obesity, which carry lower gross profit margins.
Adjusted operating income climbed 22.1% to $1.2 billion, while reported operating income reached $906.8 million, compared with $18.5 million a year earlier.
The company’s U.S. Healthcare Solutions business generated $78.3 billion in quarterly revenue, an increase of 5.4%, driven by higher pharmaceutical volumes, specialty drug sales to health systems and physician practices, and demand for GLP-1 medications.
Operating income in the U.S. segment rose 22% to $997.6 million, supported by increased pharmaceutical sales and the OneOncology acquisition.
International Healthcare Solutions reported revenue of $7.8 billion, up 5.1%, while operating income increased 16.4% to $152.1 million.
On a constant-currency basis, international revenue grew 7.8% and operating income increased 18.9%, reflecting stronger performance across the company’s international businesses.
Other operations, including MWI Animal Health and Profarma, generated $2.3 billion in revenue, up 10.1%, and operating income of $101.1 million, an increase of 35.8%.
For the full fiscal year, Cencora’s revenue rose 5% to $337.4 billion, while reported diluted earnings per share increased to $17.95 from $7.96.
Adjusted earnings per share increased 12.3% to $17.97 from $16, supported by higher gross profit and contributions from acquired businesses.
Annual adjusted operating income rose 14% to $4.8 billion, while adjusted operating margin increased 12 basis points to 1.43%.
The company’s expansion into specialty healthcare services has become a central component of its growth strategy.
“Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results,” President and Chief Executive Officer Robert P. Mauch said.
Cencora has also signed a definitive agreement to acquire American Oncology Network, a physician-led organization comprising more than 350 oncology providers across 21 states.
The proposed acquisition would further expand Cencora’s relationships with specialty physician practices and its management services capabilities.
Meanwhile, the company is narrowing its portfolio by pursuing sales of businesses outside its principal strategic priorities.
Cencora has entered into a definitive agreement to sell its stake in Profarma, with the transaction expected to close during the first quarter of fiscal 2027.
The company is also exploring strategic alternatives for MWI Animal Health and certain components of PharmaLex.
As part of its restructuring, Cencora will replace its geographic reporting structure with business-focused segments beginning in the first quarter of fiscal 2027.
The new Pharmaceutical Distribution and Services segment will include U.S. and international wholesale pharmaceutical distribution and related services for health systems, retail pharmacies and other healthcare providers.
Specialty Pharmaceutical and Provider Services will combine specialty distribution to physician practices, management services organizations, World Courier, third-party logistics, Innomar and selected PharmaLex operations.
Businesses under strategic review will remain grouped in Other.
The revised structure reflects Cencora’s effort to distinguish its traditional pharmaceutical distribution operations from its expanding specialty services businesses.
“As we enter fiscal 2027, our new operating model is designed to strengthen our execution and provide visibility to our progress,” Mauch said.
Cencora’s acquisition strategy has also increased financing costs. Fourth-quarter net interest expense rose $58.5 million to $136.3 million, primarily because of debt issued to help finance the OneOncology transaction.
The company increased its quarterly dividend by 10% to 66 cents per common share from 60 cents.
The dividend, declared Nov. 3, is payable Nov. 30 to shareholders of record as of Nov. 13.
Cencora enters fiscal 2027 with a reorganized operating structure, an expanded specialty healthcare business and a higher earnings forecast, positioning its specialty distribution and provider services operations as increasingly important contributors to future profitability.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
